按 Enter 到主內容區

CCMP100-RD-033 運用健保資料庫進行中醫藥相關議題之研究

  • 資料來源:中醫藥司
  • 建檔日期:102-08-09
  • 更新時間:106-06-15

過去研究顯示藥物交互作用所產生的不良藥物反應,其發生率高且付出的醫療成本相當可觀,在臨床上也發現國人同時使用中藥及西藥處方,有愈來愈多的趨勢,由於中醫藥在台灣民眾使用甚為普遍,而全民健康保險對中醫藥門診醫療亦有給付,不少接受癌症治療的患者亦同時尋求中醫療法以減輕化療副作用,但目前尚未有大規模資料庫相關研究以探討國人中西藥同時使用,及癌症患者中藥與抗癌藥物併用之情形,目前尚未有大規模研究加以探討。本研究目的乃針對國人同時使用中藥及西藥處方之情形做描述,並針對乳癌、子宮內膜癌、卵巢癌三大婦科癌症病患之中藥與抗癌藥物併用之頻率及存活率做描述。研究方法:本研究的設計是利用健保資料檔,採用回溯性的研究法分析全國1997~2008年,國人及乳癌、子宮內膜癌、卵巢癌三大婦科癌症病患,同時使用中藥及西藥處方之現況以及種類,同時探討國人及三大婦科癌症病患人口特質及社經特性對中西藥併用就醫行為的影響,進行藥物流行病學的調查,提供衛生署、健保局決策及施政的實證資料,維護國人用藥安全。
關鍵字:乳癌、子宮內膜癌、卵巢癌、中西藥併用、全民健保

Concurrent Use of Conventional Medicine with Traditional Chinese Medicine in Taiwan: A National Health Insurance Database Study

Drug interaction is one of the most important issues in drug safety. When the traditional Chinese medicine(TCM) become more popular, these herbs are often co-administered with therapeutic drugs raising the potential of drug–herb interactions, which may have important clinical significance based on an increasing number of clinical reports of such interactions. But there is still lack the solid data of the prevalence rate and utilization pattern of co-prescription conventional medicine and Chinese medicine products. Our research will provide the description study of the these kinds of drug herb co-administered in national health insurance system. We also try to find out the prevalence rate, survival rate and utilization pattern of the co-prescription chemotherapy and Chinese medicine products among women with breast cancer, endometrial cancer, or ovarian cancer in the national health insurance cohort 1997-2008. We hope this research can help our government to built a safe TCM environment.
關鍵字:concurrent use、Chinese medicine、herb-drug interaction、Pharmacoepidemiology